호중구감소증 생물학적 치료제 시장 보고서(2026년)

Neutropenia biologic drug treatment refers to medications used to lower the risk of fever or infection while stimulating the bone marrow to increase neutrophil production. Neutropenia occurs due to a deficiency of neutrophils, a specific type of white blood cell.

The primary drugs used in neutropenia biologic drug treatment include filgrastim, pegfilgrastim, lenograstim, lipegfilgrastim, and sargramostim. Filgrastim is a recombinant form of granulocyte colony-stimulating factor that is administered by injection to enhance neutrophil production following chemotherapy. The various treatment types include antibiotic agents, granulocyte colony-stimulating factor (G-CSF), antifungal medications, and others, and these therapies are distributed through channels such as retail pharmacies, hospital pharmacies, and online pharmacies.

Tariffs have affected the neutropenia biologic drug treatment market by increasing costs of biologic raw materials, sterile manufacturing equipment, and cold-chain transport systems. Long-acting biologics such as pegfilgrastim are more impacted due to higher production complexity. North america and europe face cost pressures because of biologics import dependence and regulatory requirements. However, tariffs are promoting local biologics production and biosimilar development. These shifts are improving treatment affordability and supply chain stability over time.

The neutropenia biologic drug treatment market research report is one of a series of new reports from The Business Research Company that provides neutropenia biologic drug treatment market statistics, including neutropenia biologic drug treatment industry global market size, regional shares, competitors with a neutropenia biologic drug treatment market share, detailed neutropenia biologic drug treatment market segments, market trends and opportunities, and any further data you may need to thrive in the neutropenia biologic drug treatment industry. This neutropenia biologic drug treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The neutropenia biologic drug treatment market size has grown strongly in recent years. It will grow from $14.78 billion in 2025 to $15.79 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to growth in cancer chemotherapy usage, approval of filgrastim-based therapies, rising infection-related hospitalizations, adoption of supportive oncology care, hospital protocol standardization.

The neutropenia biologic drug treatment market size is expected to see strong growth in the next few years. It will grow to $20.88 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to increasing oncology patient population, biosimilar penetration growth, demand for long-acting formulations, expansion of outpatient cancer care, rising healthcare expenditure. Major trends in the forecast period include increasing use of g-csf biologics, rising adoption of long-acting biologic therapies, growth in chemotherapy-induced neutropenia management, focus on biosimilars for cost reduction, expansion of hospital and oncology pharmacy distribution.

The increasing number of cancer cases worldwide is expected to support the growth of the neutropenia biologic drug treatment market. Rising cancer incidence, along with a growing number of patients undergoing chemotherapy, has led to a higher prevalence of neutropenia among cancer patients. For example, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, an estimated 165,000 Australians were newly diagnosed with cancer in 2023, representing more than 450 new cases each day, with males accounting for around 55% of these diagnoses. As a result, the global rise in cancer incidence is anticipated to increase demand for neutropenia biologic drug treatments in the coming years.

Leading companies operating in the neutropenia biologic drug treatment market are focusing on the development of biosimilars to provide more affordable alternatives to existing biologic therapies. Biosimilars are biologic medicines that are highly similar to already approved reference biologics, with no meaningful differences in safety or efficacy. For instance, in May 2023, Amneal Pharmaceuticals, a US-based pharmaceutical company, introduced Fylnetra (pegfilgrastim-pbbk), a biosimilar to Neulasta, for the prevention and treatment of febrile neutropenia in patients receiving chemotherapy. Fylnetra works by binding to specific receptors on hematopoietic cells, stimulating the growth and differentiation of neutrophil precursors in the bone marrow. This mechanism increases neutrophil production, which is essential for combating infections in patients undergoing myelosuppressive chemotherapy, thereby lowering the risk of chemotherapy-associated febrile neutropenia.

In April 2023, Assertio Holdings, Inc., a US-based specialty pharmaceutical company, acquired Spectrum Pharmaceuticals, Inc. for approximately $250 million. This acquisition is intended to strengthen Assertio's oncology portfolio, support long-term revenue growth, enhance profitability, and expand its commercial reach across specialty therapeutics. Spectrum Pharmaceuticals, Inc. is a US-based biotechnology company specializing in the development and commercialization of innovative and targeted oncology treatments.

Major companies operating in the neutropenia biologic drug treatment market are Amgen Inc., Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi S.A., GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Johnson & Johnson, Baxter International Inc., Mylan N.V., Takeda Pharmaceutical Company Limited, Bayer AG, Sun Pharmaceutical Industries Ltd., Lupin Limited, Fresenius SE & Co. KGaA, Kyowa Kirin Co. Ltd., CSL Limited, Dr. Reddy's Laboratories Ltd., Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd.

North America was the largest region in the neutropenia biologic drug treatment market in 2025. The regions covered in the neutropenia biologic drug treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the neutropenia biologic drug treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neutropenia biologic drug treatment market consists of sales of cefepime, ceftazidime, piperacillin-tazobactam, and meropenem. Values in this market are 'factory gate values', that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neutropenia Biologic Drug Treatment Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses neutropenia biologic drug treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neutropenia biologic drug treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The neutropenia biologic drug treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Type: Filgrastim; Pegfilgrastim; Lenograstim; Lipegfilgrastim; Sargramostim
• 2) By Treatment Type: Antibiotic Drugs; Granulocyte-Colony-Stimulating Factor (G-CSF); Antifungal Drugs; Other Treatment Types
• 3) By Distribution Channel: Retail Pharmacies; Hospital Pharmacies; Online Pharmacies
• Companies Mentioned: Amgen Inc.; Pfizer Inc.; Novartis AG; Teva Pharmaceutical Industries Ltd.; Sanofi S.A.; GlaxoSmithKline plc; F. Hoffmann-La Roche Ltd; Merck & Co. Inc.; Johnson & Johnson; Baxter International Inc.; Mylan N.V.; Takeda Pharmaceutical Company Limited; Bayer AG; Sun Pharmaceutical Industries Ltd.; Lupin Limited; Fresenius SE & Co. KGaA; Kyowa Kirin Co. Ltd.; CSL Limited; Dr. Reddy's Laboratories Ltd.; Astellas Pharma Inc.; Otsuka Pharmaceutical Co. Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Neutropenia Biologic Drug Treatment Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Neutropenia Biologic Drug Treatment Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Neutropenia Biologic Drug Treatment Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Neutropenia Biologic Drug Treatment Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Increasing Use Of G-Csf Biologics
  • 4.2.2 Rising Adoption Of Long-Acting Biologic Therapies
  • 4.2.3 Growth In Chemotherapy-Induced Neutropenia Management
  • 4.2.4 Focus On Biosimilars For Cost Reduction
  • 4.2.5 Expansion Of Hospital And Oncology Pharmacy Distribution

5. Neutropenia Biologic Drug Treatment Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Oncology Clinics
• 5.3 Cancer Treatment Centers
• 5.4 Hospital Pharmacies
• 5.5 Retail Pharmacies

6. Neutropenia Biologic Drug Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Neutropenia Biologic Drug Treatment Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Neutropenia Biologic Drug Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Neutropenia Biologic Drug Treatment Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Neutropenia Biologic Drug Treatment Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Neutropenia Biologic Drug Treatment Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Neutropenia Biologic Drug Treatment Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Neutropenia Biologic Drug Treatment Market Segmentation

• 9.1. Global Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Filgrastim, Pegfilgrastim, Lenograstim, Lipegfilgrastim, Sargramostim
• 9.2. Global Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Antibiotic Drugs, Granulocyte-Colony-Stimulating Factor (G-CSF), Antifungal Drugs, Other Treatment Types
• 9.3. Global Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Retail Pharmacies, Hospital Pharmacies, Online Pharmacies

10. Neutropenia Biologic Drug Treatment Market Regional And Country Analysis

• 10.1. Global Neutropenia Biologic Drug Treatment Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Neutropenia Biologic Drug Treatment Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Neutropenia Biologic Drug Treatment Market

• 11.1. Asia-Pacific Neutropenia Biologic Drug Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Segmentation By Treatment Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Neutropenia Biologic Drug Treatment Market

• 12.1. China Neutropenia Biologic Drug Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Segmentation By Treatment Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Neutropenia Biologic Drug Treatment Market

• 13.1. India Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Segmentation By Treatment Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Neutropenia Biologic Drug Treatment Market

• 14.1. Japan Neutropenia Biologic Drug Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Segmentation By Treatment Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Neutropenia Biologic Drug Treatment Market

• 15.1. Australia Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Segmentation By Treatment Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Neutropenia Biologic Drug Treatment Market

• 16.1. Indonesia Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Segmentation By Treatment Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Neutropenia Biologic Drug Treatment Market

• 17.1. South Korea Neutropenia Biologic Drug Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Segmentation By Treatment Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Neutropenia Biologic Drug Treatment Market

• 18.1. Taiwan Neutropenia Biologic Drug Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Segmentation By Treatment Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Neutropenia Biologic Drug Treatment Market

• 19.1. South East Asia Neutropenia Biologic Drug Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Segmentation By Treatment Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Neutropenia Biologic Drug Treatment Market

• 20.1. Western Europe Neutropenia Biologic Drug Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Segmentation By Treatment Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Neutropenia Biologic Drug Treatment Market

• 21.1. UK Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Segmentation By Treatment Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Neutropenia Biologic Drug Treatment Market

• 22.1. Germany Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Segmentation By Treatment Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Neutropenia Biologic Drug Treatment Market

• 23.1. France Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Segmentation By Treatment Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Neutropenia Biologic Drug Treatment Market

• 24.1. Italy Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Segmentation By Treatment Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Neutropenia Biologic Drug Treatment Market

• 25.1. Spain Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Segmentation By Treatment Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Neutropenia Biologic Drug Treatment Market

• 26.1. Eastern Europe Neutropenia Biologic Drug Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Segmentation By Treatment Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Neutropenia Biologic Drug Treatment Market

• 27.1. Russia Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Segmentation By Treatment Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Neutropenia Biologic Drug Treatment Market

• 28.1. North America Neutropenia Biologic Drug Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Segmentation By Treatment Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Neutropenia Biologic Drug Treatment Market

• 29.1. USA Neutropenia Biologic Drug Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Segmentation By Treatment Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Neutropenia Biologic Drug Treatment Market

• 30.1. Canada Neutropenia Biologic Drug Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Segmentation By Treatment Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Neutropenia Biologic Drug Treatment Market

• 31.1. South America Neutropenia Biologic Drug Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Segmentation By Treatment Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Neutropenia Biologic Drug Treatment Market

• 32.1. Brazil Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Segmentation By Treatment Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Neutropenia Biologic Drug Treatment Market

• 33.1. Middle East Neutropenia Biologic Drug Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Segmentation By Treatment Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Neutropenia Biologic Drug Treatment Market

• 34.1. Africa Neutropenia Biologic Drug Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Segmentation By Treatment Type, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Neutropenia Biologic Drug Treatment Market Regulatory and Investment Landscape

36. Neutropenia Biologic Drug Treatment Market Competitive Landscape And Company Profiles

• 36.1. Neutropenia Biologic Drug Treatment Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Neutropenia Biologic Drug Treatment Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Neutropenia Biologic Drug Treatment Market Company Profiles
  • 36.3.1. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

37. Neutropenia Biologic Drug Treatment Market Other Major And Innovative Companies

• GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Johnson & Johnson, Baxter International Inc., Mylan N.V., Takeda Pharmaceutical Company Limited, Bayer AG, Sun Pharmaceutical Industries Ltd., Lupin Limited, Fresenius SE & Co. KGaA, Kyowa Kirin Co. Ltd., CSL Limited, Dr. Reddy's Laboratories Ltd., Astellas Pharma Inc.

38. Global Neutropenia Biologic Drug Treatment Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Neutropenia Biologic Drug Treatment Market

40. Neutropenia Biologic Drug Treatment Market High Potential Countries, Segments and Strategies

• 40.1 Neutropenia Biologic Drug Treatment Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Neutropenia Biologic Drug Treatment Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Neutropenia Biologic Drug Treatment Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer